Human serum albumin conjugated biomolecules for cancer molecular imaging

Current Pharmaceutical Design

Volumn 18, Issue 8, 2012, Pages 1023-1031

  Yang, Meng ^a,b   Hoppmann, Susan ^a   Chen, Luxi ^a   Cheng, Zhen ^a  

^a STANFORD UNIVERSITY   (United States)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Cancer; Human serum albumin (HSA); Molecular imaging; Optical imaging; PET

Indexed keywords

ALBUMIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOLIC ACID; GADOBENATE DIMEGLUMINE; GADOCOLETIC ACID; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; NANOPARTICLE; TECHNETIUM 99M; TETRAXETAN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG;

ALBUMIN BLOOD LEVEL; ANGIOGENESIS; BINDING AFFINITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; KIDNEY CLEARANCE; LUNG NON SMALL CELL CANCER; MOLECULAR IMAGING; MOLECULAR PROBE; MOLECULAR WEIGHT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA HALF LIFE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN STABILITY; RADIATION DOSE; RADIATION EXPOSURE; RADIOACTIVITY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STOICHIOMETRY;

ANIMALS; HALF-LIFE; HUMANS; MOLECULAR IMAGING; MOLECULAR PROBES; NEOPLASMS; SERUM ALBUMIN; TISSUE DISTRIBUTION;

EID: 84863138153     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799315830     Document Type: Review

References (80)

1. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003; 17(5): 545-80.
2. Carter DC, Ho JX. Structure of serum albumin. Adv Protein Chem 1994; 45: 153-203.
3. Peters T, Jr. Serum albumin. Adv Protein Chem 1985; 37: 161-245.
4. Jeong H, Huh M, Lee SJ, et al. Photosensitizer-conjugated human serum albumin nanoparticles for effective photodynamic therapy. Theranostics 2011; 1: 230-9.
5. Iancu C, Mocan L, Bele C, et al. Enhanced laser thermal ablation for the in vitro treatment of liver cancer by specific delivery of multiwalled carbon nanotubes functionalized with human serum albumin. Int J Nanomedicine 2011; 6: 129-41.
6. Mocan L, Tabaran FA, Mocan T, et al. Selective ex-vivo photothermal ablation of human pancreatic cancer with albumin functionalized multiwalled carbon nanotubes. Int J Nanomedicine 2011; 6: 915-28.
7. Carter DC, He XM. Structure of human serum albumin. Science 1990; 249(4966): 302-3.
8. Carter DC, He XM, Munson SH, et al. Three-dimensional structure of human serum albumin. Science 1989; 244(4909): 1195-8.
9. He XM, Carter DC. Atomic structure and chemistry of human serum albumin. Nature 1992; 358(6383): 209-15.
10. Zunszain PA, Ghuman J, Komatsu T, Tsuchida E, Curry S. Crystal structural analysis of human serum albumin complexed with hemin and fatty acid. BMC Struct Biol 2003; 3: 6.
11. Bhattacharya AA, Grune T, Curry S. Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J Mol Biol 2000; 303(5): 721-32.
12. Curry S, Mandelkow H, Brick P, Franks N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat Struct Biol 1998; 5(9): 827-35.
13. Dockal M, Carter DC, Ruker F. The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties. J Biol Chem 1999; 274(41): 29303-10.
14. Sugio S, Kashima A, Mochizuki S, Noda M, Kobayashi K. Crystal structure of human serum albumin at 2.5 A resolution. Protein Eng 1999; 12(6): 439-46.
15. Bhattacharya AA, Curry S, Franks NP. Binding of the general anesthetics propofol and halothane to human serum albumin. High resolution crystal structures. J Biol Chem 2000; 275(49): 38731-8.
16. Fasano M, Baroni S, Vannini A, Ascenzi P, Aime S. Relaxometric characterization of human hemalbumin. J Biol Inorg Chem 2001; 6(5-6): 650-8.
17. Mattu M, Vannin A, Coletta M, Fasano M, Ascenzi P. Effect of bezafibrate and clofibrate on the heme-iron geometry of ferrous nitrosylated heme-human serum albumin: an EPR study. J Inorg Biochem 2001; 84(3-4): 293-6.
18. Hamilton JA. Fatty acid interactions with proteins: what X-ray crystal and NMR solution structures tell us. Prog Lipid Res 2004; 43(3): 177-99.
19. Sakurai Y, Ma SF, Watanabe H, et al. Esterase-like activity of serum albumin: characterization of its structural chemistry using pnitrophenyl esters as substrates. Pharm Res 2004; 21(2): 285-92.
20. Petitpas I, Petersen CE, Ha CE, et al. Structural basis of albuminthyroxine interactions and familial dysalbuminemic hyperthyroxinemia. Proc Natl Acad Sci U S A 2003; 100(11): 6440-5.
21. Dockal M, Chang M, Carter DC, Ruker F. Five recombinant fragments of human serum albumin-tools for the characterization of the warfarin binding site. Protein Sci 2000; 9(8): 1455-65.
22. Curry S. Lessons from the crystallographic analysis of small molecule binding to human serum albumin. Drug Metab Pharmacokinet 2009; 24(4): 342-57.
23. Liang Hong, Xing Bengang, Wu Qingxuan, et al. Study on the interaction of human serum albumin with Cu (II) and Fe (III) by fluorescence method. Acta Chim Sinica 1999; 57(2): 161-5.
24. Walle T, Vincent TS, Walle UK. Evidence of covalent binding of the dietary flavonoid quercetin to DNA and protein in human intestinal and hepatic cells. Biochem Pharmacol 2003; 65(10): 1603-10.
25. Fiume L, Bassi B, Bongini A. Conjugates of 9-beta-Darabinofuranosyladenine 5'-monophosphate (ara-AMP) with lactosaminated albumin. Characterization of the drug-carrier bonds. Pharm Acta Helv 1988; 63(4-5): 137-9.
26. Yapel AF, Jr. Albumin microspheres: heat and chemical stabilization. Methods Enzymol 1985; 112: 1-18.
27. Ascenzi P, Bocedi A, Notari S, Fanali G, Fesce R, Fasano M. Allosteric modulation of drug binding to human serum albumin. Mini Rev Med Chem 2006; 6(4): 483-9.
28. Ding A, Zia-Amirhosseini P, McDonagh AF, Burlingame AL, Benet LZ. Reactivity of tolmetin glucuronide with human serum albumin. Identification of binding sites and mechanisms of reaction by tandem mass spectrometry. Drug Metab Dispos 1995; 23(3): 369-76.
29. Benet LZ, Spahn-Langguth H, Iwakawa S, et al. Predictability of the covalent binding of acidic drugs in man. Life Sci 1993; 53(8): PL141-6.
30. Kragh-Hansen U, Chuang VT, Otagiri M. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull 2002; 25(6): 695-704.
31. Wong SY, Guile GR, Dwek RA, Arsequell G. Synthetic glycosylation of proteins using N-(beta-saccharide) iodoacetamides: applications in site-specific glycosylation and solid-phase enzymic oligosaccharide synthesis. Biochem J 1994; 300 (Pt 3): 843-50.
32. Barrett T, Kobayashi H, Brechbiel M, Choyke PL. Macromolecular MRI contrast agents for imaging tumor angiogenesis. Eur J Radiol 2006; 60(3): 353-66.
33. Fasano M, Curry S, Terreno E, et al. The extraordinary ligand binding properties of human serum albumin. IUBMB Life 2005; 57(12): 787-96.
34. Hoppmann S, Miao Z, Liu S, et al. Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting. Bioconjug Chem 2011; 22(3): 413-21.
35. Ulbrich K, Michaelis M, Rothweiler F, et al. Interaction of folateconjugated human serum albumin (HSA) nanoparticles with tumour cells. Int J Pharm 2011; 406(1-2): 128-34.
36. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. Chem Rev 1999; 99(9): 2293-352.
37. Lauffer RB, Parmelee DJ, Dunham SU, et al. MS-325: albumintargeted contrast agent for MR angiography. Radiology 1998; 207(2): 529-38.
38. Schmiedl U, Ogan MD, Moseley ME, Brasch RC. Comparison of the contrast-enhancing properties of albumin-(Gd-DTPA) and Gd- DTPA at 2.0 T: and experimental study in rats. AJR Am J Roentgenol 1986; 147(6): 1263-70.
39. Ogan MD, Schmiedl U, Moseley ME, Grodd W, Paajanen H, Brasch RC. Albumin labeled with Gd-DTPA. An intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization. Invest Radiol 1987; 22(8): 665-71.
40. Murad GJ, Walbridge S, Morrison PF, et al. Real-time, imageguided, convection-enhanced delivery of interleukin 13 bound to pseudomonas exotoxin. Clin Cancer Res 2006; 12(10): 3145-51.
41. Gossmann A, Okuhata Y, Shames DM, et al. Prostate cancer tumor grade differentiation with dynamic contrast-enhanced MR imaging in the rat: comparison of macromolecular and small-molecular contrast media--preliminary experience. Radiology 1999; 213(1): 265-72.
42. Turetschek K, Huber S, Floyd E, et al. MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. Radiology 2001; 218(2): 562-9.
43. Turetschek K, Floyd E, Helbich T, et al. MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histopathology. J Magn Reson Imaging 2001; 14(3): 237-42.
44. Turetschek K, Floyd E, Shames DM, et al. Assessment of a rapid clearance blood pool MR contrast medium (P792) for assays of microvascular characteristics in experimental breast tumors with correlations to histopathology. Magn Reson Med 2001; 45(5): 880-6.
45. Fields T, Kaplan E, Terril M. A simplified technique for blood volume determinations using I131 HSA. J Lab Clin Med 1954; 43(2): 332-4.
46. Mathias CJ, Bergmann SR, Green MA. Species-dependent binding of copper(II) bis(thiosemicarbazone) radiopharmaceuticals to serum albumin. J Nucl Med 1995; 36(8): 1451-5.
47. Chuang VT, Otagiri M. Recombinant human serum albumin. Drugs Today (Barc) 2007; 43(8): 547-61.
48. Chen K, Xie J, Chen X. RGD-human serum albumin conjugates as efficient tumor targeting probes. Mol Imaging 2009; 8(2): 65-73.
49. Sampson JH, Brady M, Raghavan R, et al. Co-localization of gadolinium-DTPA with high molecular weight molecules after intracerebral convection-enhanced delivery in man. Neurosurgery 2011; 69(3): 668-76.
50. Kim S, Kim HK, Kang DY, Jeong JM, Choi YH. Intra-operative sentinel lymph node identification using a novel receptor-binding agent (technetium-99m neomannosyl human serum albumin, 99mTc-MSA) in stage I non-small cell lung cancer. Eur J Cardiothorac Surg 2010; 37(6): 1450-6.
51. Kim HK, Kim S, Park JJ, Jeong JM, Mok YJ, Choi YH. Sentinel node identification using technetium-99m neomannosyl human serum albumin in esophageal cancer. Ann Thorac Surg 2011; 91(5): 1517-22.
52. Dennis MS, Jin H, Dugger D, et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res 2007; 67(1): 254-61.
53. Muller N, Schneider B, Pfizenmaier K, Wajant H. Superior serum half life of albumin tagged TNF ligands. Biochem Biophys Res Commun 2010; 396(4): 793-9.
54. Furukawa M, Tanaka R, Chuang VT, et al. Human serum albuminthioredoxin fusion protein with long blood retention property is effective in suppressing lung injury. J Control Release 2011; 154(2): 189-95.
55. Bingfa X, Qinglin F, Hui H, Canjun W, Wei W, Lihua S. Antihepatitis B virus activity and mechanisms of recombinant human serum albumin-interferon-alpha-2b fusion protein in vitro and in vivo. Pharmacology 2009; 83(6): 323-32.
56. Chen JH, Zhang XG, Jiang YT, et al. Bioactivity and pharmacokinetics of two human serum albumin-thymosin alpha1-fusion proteins, rHSA-Talpha1 and rHSA-L-Talpha1, expressed in recombinant Pichia pastoris. Cancer Immunol Immunother 2010; 59(9): 1335-45.
57. Clumeck N, Wit SD, Hermans P, Franchioly P, Sommereijns B. Recombinant granulocyte colony-stimulating factor (rG-CSF) in HIV patients with zidovudine related neutropenia. J Nutr Sci Vitaminol (Tokyo) 1992; Spec No: 353-6.
58. Sheffield WP, Gataiance S, Eltringham-Smith LJ. Combined administration of barbourin--albumin and hirudin--albumin fusion proteins limits fibrin(ogen) deposition on the rabbit balloon-injured aorta. Thromb Res 2007; 119(2): 195-207.
59. Yeh P, Landais D, Lemaitre M, et al. Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate. Proc Natl Acad Sci USA 1992; 89(5): 1904-8.
60. Choi N, Kim SM, Hong KS, et al. The use of the fusion protein RGD-HSA-TIMP2 as a tumor targeting imaging probe for SPECT and PET. Biomaterials 2011; 32(29): 7151-8.
61. Yazaki PJ, Kassa T, Cheung CW, et al. Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein. Nucl Med Biol 2008; 35(2): 151-8.
62. Tolmachev V, Wallberg H, Andersson K, Wennborg A, Lundqvist H, Orlova A. The influence of Bz-DOTA and CHX-A"-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy. Eur J Nucl Med Mol Imaging 2009; 36(9): 1460-8.
63. Tolmachev V, Orlova A, Pehrson R, et al. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res 2007; 67(6): 2773-82.
64. Geraldes CF, Urbano AM, Alpoim MC, et al. Preparation, physicochemical characterization, and relaxometry studies of various gadolinium(III)-DTPA-bis(amide) derivatives as potential magnetic resonance contrast agents. Magn Reson Imaging 1995; 13(3): 401-20.
65. Lauffer RB, Parmelee DJ, Ouellet HS, et al. MS-325: a smallmolecule vascular imaging agent for magnetic resonance imaging. Acad Radiol 1996; 3 Suppl 2: S356-8.
66. Grist TM, Korosec FR, Peters DC, et al. Steady-state and dynamic MR angiography with MS-325: initial experience in humans. Radiology 1998; 207(2): 539-44.
67. Prasad PV, Cannillo J, Chavez DR, et al. First-pass renal perfusion imaging using MS-325, an albumin-targeted MRI contrast agent. Invest Radiol 1999; 34(9): 566-71.
68. Jeong JM, Hong MK, Kim YJ, et al. Development of 99mTcneomannosyl human serum albumin (99mTc-MSA) as a novel receptor binding agent for sentinel lymph node imaging. Nucl Med Commun 2004; 25(12): 1211-7.
69. Turetschek K, Roberts TP, Floyd E, et al. Tumor microvascular characterization using ultrasmall superparamagnetic iron oxide particles (USPIO) in an experimental breast cancer model. J Magn Reson Imaging 2001; 13(6): 882-8.
70. Zhang Z, Nair SA, McMurry TJ. Gadolinium meets medicinal chemistry: MRI contrast agent development. Curr Med Chem 2005; 12(7): 751-78.
71. Schmiedl U, Ogan M, Paajanen H, et al. Albumin labeled with Gd-DTPA as an intravascular, blood pool-enhancing agent for MR imaging: biodistribution and imaging studies. Radiology 1987; 162(1 Pt 1): 205-10.
72. Xie J, Wang J, Niu G, et al. Human serum albumin coated iron oxide nanoparticles for efficient cell labeling. Chem Commun (Camb) 2010; 46(3): 433-5.
73. Ntziachristos V, Bremer C, Weissleder R. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol 2003; 13(1): 195-208.
74. Achilefu S. Lighting up tumors with receptor-specific optical molecular probes. Technol Cancer Res Treat 2004; 3(4): 393-409.
75. Awasthi K, Nishimura G. Modification of near-infrared cyanine dyes by serum albumin protein. Photochem Photobiol Sci 2011; 10(4): 461-3.
76. Gunn AJ, Hama Y, Koyama Y, Kohn EC, Choyke PL, Kobayashi H. Targeted optical fluorescence imaging of human ovarian adenocarcinoma using a galactosyl serum albumin-conjugated fluorophore. Cancer Sci 2007; 98(11): 1727-33.
77. Hama Y, Urano Y, Koyama Y, Gunn AJ, Choyke PL, Kobayashi H. A self-quenched galactosamine-serum albumin-rhodamineX conjugate: a smart fluorescent molecular imaging probe synthesized with clinically applicable material for detecting peritoneal ovarian cancer metastases. Clin Cancer Res 2007; 13(21): 6335-43.
78. Regino CA, Ogawa M, Alford R, et al. Two-step synthesis of galactosylated human serum albumin as a targeted optical imaging agent for peritoneal carcinomatosis. J Med Chem 2010; 53(4): 1579-86.
79. Ohnishi S, Lomnes SJ, Laurence RG, Gogbashian A, Mariani G, Frangioni JV. Organic alternatives to quantum dots for intraoperative near-infrared fluorescent sentinel lymph node mapping. Mol Imaging 2005; 4(3): 172-81.
80. Parungo CP, Ohnishi S, De Grand AM, et al. In vivo optical imaging of pleural space drainage to lymph nodes of prognostic significance. Ann Surg Oncol 2004; 11(12): 1085-92.